Novel 5-(3-aryl-2-propynyl)-5-(arylsulfonyl)thiazolidine-2,4-diones as antihyperglycemic agents

Journal of Medicinal Chemistry

Volumn 41, Issue 7, 1998, Pages 1084-1091

  Wrobel, Jay ^a,b   Li, Zenan ^a   Dietrich, Arlene ^a   McCaleb, Michael ^a,c   Mihan, Brenda ^a   Sredy, Janet ^a,d   Sullivan, Donald ^a  

^a PFIZER INC   (United States)

^b WYETH AYERST RESEARCH   (United States)

^c AMGEN INC   (United States)

^d The Institute for Diabetes Discovery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 (3 ARYL 2 PROPYNYL) 5 (ARYLSULFANYL)THIAZOLIDINE 2,4 DIONE DERIVATIVE; 5 (3 ARYL 2 PROPYNYL) 5 (ARYLSULFONYL)THIAZOLIDINE 2,4 DIONE DERIVATIVE; ANTIDIABETIC AGENT; CIGLITAZONE; GLUCOSE; INSULIN; TOLBUTAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORAL DRUG ADMINISTRATION; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; BLOOD GLUCOSE; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED C57BL; RATS; RATS, ZUCKER; SULFONES; THIAZOLES;

EID: 0032568401     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9706168     Document Type: Article

References (22)

1. Kahn, C. R. Insulin Action, Diabetogenes, and the Cause of Type II Diabetes. Diabetes 1994, 43, 1066-1084.
2. The Diabetes Control and Complications Trial Research Group: The Effect of Intensive Treatment of Diabetes on the Development and Progression of Longterm Complications in Insulin-Dependent Diabetes Melitus. N. Engl. J. Med. 1993, 329, 977-986.
3. Witcher, J. W. Implications of the DCCT. A Pharmaceutical Industry Viewpoint and Commentary. Diabetes Rev. 1994, 2, 272-276.
4. Sohda, T.; Mizuno, K.; Imamiya, E.; Sugiyama, Y.; Fujita, T.; Kawamatsu, Y. Studies on Antidiabetic Agents. II. Synthesis of 5-[4-(1-Methylcylohexylmethoxy)-benzyl]thiazolidine-2,4-dione (ADD-3878) and its Derivatives. Chem. Pharm. Bull. 1982, 30, 3580-3600.
5. Chang, A. Y.; Wyse, B. M.; Gilchrist, B. J.; Peterson, T.; Diani, R. Ciglitazone, a New Hypoglycemic Agent. 1. Studies in ob/ob and db/db Mice, Chinese Hamsters and Normal and Streptozotocin-Diabetic Rats. Diabetes 1983, 32, 830-838.
6. Sohda, T.; Mizuno, K.; Momose, Y.; Ikeda, H.; Fujita, T.; Meguro, K. Studies on Antidiabetic Agents. 11. Novel Thiazolidinedione Derivatives as Potent Hypoglycemic and Hypolipidemic Agents. J. Med. Chem. 1992, 35, 2617-2626.
7. Yu, M. M.; Meguro, K.; Ikeda, H.; Hatanaka, C.; Oi, S.; Sohda, T. Studies on Antidiabetic Agents. 10. Synthesis and Biological Activities of Pioglitazone and Related Compounds. Chem. Pharm. Bull. 1991, 39, 1440-1445.
8. Clark, D. A.; Goldstein, S. W.; Volkmann, R. A.; Eggler, J. F.; Holland, G. F.; Hulin, B.; Stevenson, R. W.; Kreutter, D. K.; Gibbs, E. M.; Krupp, M. N.; Merrigan, P.; Kelbaugh, P. L.; Andrews, E. G.; Tickner, D. L.; Suleske, R. T.; Lamphere, C. H.; Rajeckas, F. J.; Kappeler, W. H.; McDermott, R. E.; Hutson, N. J.; Johnson, M. R. Substituted Dihydrobenzopyran and Dihydrobenzofuran Thiazolidine-2,4-diones as Hypoglycemic Agents. J. Med. Chem. 1991, 34, 319-325.
9. Hulin, B.; Clark, D. A.; Goldstein, S. W.; McDermott, R. E.; Dambek, P. J.; Kappeler, W. H.; Lamphere, C. H.; Lewis, D. M.; Rizzi, J. P. Novel Thiazolidine-2,4-diones as Potent Euglycemic Agents. J. Med. Chem. 1992, 55, 1853-1864.
10. Cantello, B. C. C.; Cawthorne, M. A.; Cottam, G. P.; Duff, P. T.; Haigh, D.; Hindley, R. M.; Lister, C. A.; Smith, S. A.; Thurlby, P. L. [[ω-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as Potent Antihyperglycemic Agents. J. Med. Chem. 1994, 37, 3977-3985.
11. Kumar, S.; Boulton, A. J. M.; Beck-Nielsen, H.; Berthezene, F.; Muggeo, M.; Persson, B.; Spinas, G. A.; Donoghue, S.; Lettis, S.; Stewart-Long, P.; for the Troglitazone study group Troglitazone, an Insulin Action Enhancer, Improves Metabolic Control in NIDDM Patients. Diabetologia 1996, 30, 701-709.
12. Kuehnle, H. F.; Wolff, H. P.; Haring, H. U.; Wieland, O.; Strein, K. BM 13.0907. A New Oral Hypoglycemic Agent with an Effect on Insulin Resistance. Arch. Pharmacol. 1989, 340, (suppl. R40), Abstract 117.
13. Obermaier-Kusser, B.; Muhlbacher, C.; Mushack, J.; Seffer, E.; Ermel, B.; Machicao, F.; Schmidt, F.; Haring, H. U. Further Evidence for a Two-Step Model of Glucose Transport Regulation. Biochem. J. 1989, 261, 699-705.
14. Freund, P.; Wolff, H. P.; Kuehnle, H. F. (-)-BM 13.0913: A New Oral Antidiabetic Agent that Improves Insulin Sensitivity in Animal Models of Type II (non-insulin dependent) Diabetes Mellitus. Metabolism 1995, 44, 570-576.
15. Heitzmann, T.; Neidlein, R.; Freund, P.; Strein, K. Pharmacokinetics of the New Oral Blood Glucose Lowering Agent (-)2-(4-tert-Butylphenoxy)-7-(4-chlorophenyl)-heptanoic Acid Sodium Salt in Mice, Rats and Dogs. Araneim.-Forsch. / Drug Res. 1995, 45(II),
16. Sarges, R.; Hank, R. F.; Blake, J. F.; Bordner, J.; Bussolotti, D. L.; Hargrove, D. M.; Treadway, J. L.; Gibbs, E. M. Glucose Transport-Enhancing and Hypoglycemic Activity of 2-methyl-2-phenoxy-3-phenylpropanoic Acids. J. Med. Chem. 1996, 39, 4783-4803.
17. Zask, A.; Jirkovsky, I.; Nowicki, J. W.; McCaleb, M. L. Synthesis and Antihyperglycemic Activity of Novel 5-(Naphthalenylsulfonyl)-2,4-thiazolidinediones. J. Med. Chem. 1990, 33, 1418-1423.
18. Coleman, D. L.; Hummel, K. P. Studies with the Mutation, Diabetes in the Mouse. Diabetologia 1967, 3, 238-248.
19. Tutwiler, G. F.; Kirsch, T.; Bridi, G. A Pharmacologic Profile of McN-3495 [N-(1-Methyl-2-pyrrolidinylidene)-N'-Phenyl-1-pyrrolidinecarboxamide], a New, Orally Effective Hypoglycemic Agent. Diabetes 1978, 27, 855-867.
20. Still, W. C.; Kahn, M.; Mitra, A. Rapid Chromatographic Technique for Preparative Separations with Moderate Resolution. J. Org. Chem. 1978, 43, 2923-2925.
21. Dunn, A. D.; Norrie, R.; L'Hostis, J.; Marjot, S. The synthesis and some reactions of novel pyridine-2(1H)-thiones. J. Prakt. Chem. / Chem.-Ztg. 1992, 334, 119-25.
22. Heding, L. G. Determination of Total Serum Insulin (IRI) in Insulin-treated Diabetic Patients. Diabetalogia 1972, 8, 260-266.